Vaccines

Vaccines are a clinical product that is composed of live or dead material from an infectious agent – bacterium, virus, fungus or parasite – that elicit protective immunity against the pathogen when administered. These substances are used to prevent the spread of infectious diseases.

Featured

News & Views | 28 July 2022

PD-1 blockade unblocks immune responses to vaccination
- Katherine Kedzierska
- & Thi H. O. Nguyen
Nature Immunology 23, 1135-1137
News & Views | 22 July 2022

A new route to vaccines using PROTACs
- Brad Gilbertson
- & Kanta Subbarao
Nature Biotechnology, 1-2

Latest Research and Reviews

Research
09 August 2022 | Open Access

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

The public health concern caused by influenza B virus is often overlooked, yet represents a significant global burden. Here, the authors evaluate the cellular and humoral immune responses of multivalent vaccine candidates, based on the lipid nanoparticle-encapsulated nucleoside-modified mRNA platform, and demonstrate protection of mice from challenge with a broad panel of influenza B viruses.
- Norbert Pardi
- , Juan Manuel Carreño
- & Meagan McMahon
Nature Communications 13, 4677
Research
08 August 2022 | Open Access

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

Whilst the ChAdOx1 nCoV-19 (AZD1222) vaccine has demonstrated efficacy against symptomatic disease, variants of concern (VOCs) with spike protein substitutions have led researchers to explore updating vaccines from ancestral spike protein. Authors use a Syrian hamster model to evaluate a vaccine encoding the spike protein of Beta VOC and assess efficacy against VOCs.
- Neeltje van Doremalen
- , Jonathan E. Schulz
- & Vincent J. Munster
Nature Communications 13, 4610
Research
08 August 2022 | Open Access

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Here the authors show that a third SARS-CoV-2 vaccination significantly boosts neutralizing antibodies against Omicron subvariants and that hybrid immunity (infection and vaccination) results in broader neutralization activity and cross-reactive antibody affinity maturation.
- Lorenza Bellusci
- , Gabrielle Grubbs
- & Surender Khurana
Nature Communications 13, 4617
Research
08 August 2022 | Open Access

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

Responses to SARS-CoV-2 vaccines in different populations are important to define efficacy. Here the authors show using a cohort in Singapore that two doses of mRNA vaccine is less effective in recipients over 60 years of age and that a further dose of vaccine can improve these antibody levels.
- Laurent Renia
- , Yun Shan Goh
- & Lisa F. P. Ng
Nature Communications 13, 4615
Research
08 August 2022 | Open Access

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

Vaccines induce beneficial immunity for COVID-19, but immune waning prompts boosting vaccination. Here, the authors show that a third, boosting dose of COVID-19 mRNA vaccine induces transient CD8 + T effector cell response while conserving the CD8 memory T cell pool, thereby permitting reactivation of spike-specific CD8 + T cells upon breakthrough infection or 4th vaccination.
- Matthias Reinscheid
- , Hendrik Luxenburger
- & Maike Hofmann
Nature Communications 13, 4631
Research
06 August 2022 | Open Access

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

A longitudinal study in mice reveals that a booster dose of mRNA vaccine BNT162b2 enhances humoral and cell-mediated responses and provides sterilizing immunity against Omicron-induced lung infection in aged animals.
- Etsuro Nanishi
- , Marisa E. McGrath
- & David J. Dowling
Communications Biology 5, 790

All Research & Reviews

News and Comment

Research Highlights | 09 August 2022

Vaccination to prevent untreatable gonorrhoea
- Maria Chiara Masone
Nature Reviews Urology, 1
Comments & Opinion | 09 August 2022

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?

Hybrid immunity occurs in those who have been both infected with and vaccinated against SARS-CoV-2. But how well does such hybrid immunity protect against the virus and its emerging variants?
- Rahul Suryawanshi
- & Melanie Ott
Nature Reviews Immunology, 1-2
Editorial | 03 August 2022

Get childhood immunizations back on track after COVID

The effects of the pandemic mean childhood vaccination rates are the lowest for a generation. There is a risk of preventable diseases resurging unless governments treat this as a priority.

Nature 608, 7-8
Comments & Opinion
02 August 2022 | Open Access

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame
- James A. Triccas
- , Joeri Kint
- & Florian M. Wurm
npj Vaccines 7, 89
News & Views | 28 July 2022

PD-1 blockade unblocks immune responses to vaccination

Wherry and colleagues describe how anti-PD-1 immunotherapy impacts outcomes of influenza vaccination in patients with cancer, and specifically, how it increases seroconversion and affects quantitative and qualitative aspects of antibodies and follicular T helper cell responses.
- Katherine Kedzierska
- & Thi H. O. Nguyen
Nature Immunology 23, 1135-1137
News | 26 July 2022

Pandemic drives largest drop in childhood vaccinations in 30 years

Last year alone, 25 million children missed out on immunizations against infections such as measles and polio, leading to avoidable outbreaks of disease.
- Giorgia Guglielmi
Nature 608, 253

All News & Comment

Vaccines

Featured

PD-1 blockade unblocks immune responses to vaccination

A new route to vaccines using PROTACs

Latest Research and Reviews

Development of a pentavalent broadly protective nucleoside-modified mRNA vaccine against influenza B viruses

ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants

Antibody affinity and cross-variant neutralization of SARS-CoV-2 Omicron BA.1, BA.2 and BA.3 following third mRNA vaccination

Lower vaccine-acquired immunity in the elderly population following two-dose BNT162b2 vaccination is alleviated by a third vaccine dose

COVID-19 mRNA booster vaccine induces transient CD8+ T effector cell responses while conserving the memory pool for subsequent reactivation

mRNA booster vaccination protects aged mice against the SARS-CoV-2 Omicron variant

News and Comment

Vaccination to prevent untreatable gonorrhoea

SARS-CoV-2 hybrid immunity: silver bullet or silver lining?

Get childhood immunizations back on track after COVID

Affordable SARS-CoV-2 protein vaccines for the pandemic endgame

PD-1 blockade unblocks immune responses to vaccination

Pandemic drives largest drop in childhood vaccinations in 30 years

Quick links

Discover content

Publishing policies

Author & Researcher services

Libraries & institutions

Advertising & partnerships

Career development

Regional websites

Legal & Privacy

Vaccines

Featured

Related Subjects

Latest Research and Reviews

News and Comment

Search

Quick links